Vertex Pharmaceuticals (VRTX) to Release Quarterly Earnings on Monday

Vertex Pharmaceuticals (NASDAQ:VRTX) is expected to release its Q1 2025 earnings data after the market closes on Monday, May 5th. Analysts expect Vertex Pharmaceuticals to post earnings of $4.24 per share and revenue of $2.85 billion for the quarter. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. On average, analysts expect Vertex Pharmaceuticals to post $16 EPS for the current fiscal year and $18 EPS for the next fiscal year.

Vertex Pharmaceuticals Stock Up 0.5 %

Shares of NASDAQ:VRTX opened at $501.15 on Friday. Vertex Pharmaceuticals has a 12-month low of $377.85 and a 12-month high of $519.88. The stock has a market capitalization of $128.84 billion, a price-to-earnings ratio of -227.80, a PEG ratio of 2.11 and a beta of 0.50. The stock has a fifty day simple moving average of $492.00 and a two-hundred day simple moving average of $467.15. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 244 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $455.06, for a total transaction of $111,034.64. Following the transaction, the executive vice president now owns 67,695 shares of the company’s stock, valued at approximately $30,805,286.70. This trade represents a 0.36 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP David Altshuler sold 3,231 shares of the business’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $500.00, for a total value of $1,615,500.00. Following the completion of the transaction, the executive vice president now directly owns 26,512 shares of the company’s stock, valued at approximately $13,256,000. The trade was a 10.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 4,315 shares of company stock worth $2,121,012 in the last ninety days. 0.20% of the stock is owned by company insiders.

Institutional Trading of Vertex Pharmaceuticals

An institutional investor recently raised its position in Vertex Pharmaceuticals stock. Brighton Jones LLC boosted its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 15.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 4,427 shares of the pharmaceutical company’s stock after purchasing an additional 579 shares during the period. Brighton Jones LLC’s holdings in Vertex Pharmaceuticals were worth $1,783,000 at the end of the most recent reporting period. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Barclays upped their target price on shares of Vertex Pharmaceuticals from $435.00 to $467.00 and gave the company an “equal weight” rating in a report on Tuesday, February 11th. BMO Capital Markets set a $545.00 target price on Vertex Pharmaceuticals in a research report on Friday, January 31st. Morgan Stanley increased their price objective on shares of Vertex Pharmaceuticals from $450.00 to $459.00 and gave the company an “equal weight” rating in a report on Tuesday, February 11th. Wells Fargo & Company downgraded shares of Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $460.00 target price on the stock. in a report on Thursday, January 30th. Finally, Piper Sandler cut their target price on shares of Vertex Pharmaceuticals from $535.00 to $533.00 and set an “overweight” rating for the company in a research note on Monday, January 27th. Ten equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $514.91.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.